Safe Surf Rated - www.safesurf.com Back To Home Page Family Friendly Site - www.familyfriendlysites.com
About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV and AIDS News spacer.gif Bradford McIntyre spacer.gif
spacer.gif
   
AIDS Awareness Red Ribbon


CATIE - www.catie.ca

Truvada approved for HIV prevention in Canada

29 February 2016 - In an exciting development, on February 26 th 2016 Health Canada approved the use of Truvada taken every day for the prevention of sexual transmission of HIV.

Truvada is a pill containing the following two anti-HIV drugs:

  • tenofovir DF – 300 mg
  • FTC (emtricitabine) – 200 mg

Taking medicines to prevent infection in HIV-negative people is called pre-exposure prophylaxis (PrEP).

Health Canada has approved the daily use of Truvada as part of a suite of prevention measures including the following:

  • testing for HIV prior to initiation of Truvada
  • screening for and, when necessary, treatment of sexually transmitted infections
  • regular and frequent testing for HIV while using Truvada
  • the use of condoms

Health Canada based its approval on data from clinical trials in men who have sex with men as well as in heterosexual couples where one partner was HIV-positive. In these studies, Truvada was taken once daily every day together with the suite of previously mentioned prevention measures. In this context Truvada was highly effective in preventing new cases of HIV infection.

What's next?

Truvada costs about $1,000 per month. To facilitate access, private insurance companies need to move swiftly to add Truvada (when used as PrEP) to their list of reimbursed medicines.

However, not everyone at high risk for HIV has private insurance. Canada's provinces and territories now need to consider adding PrEP to their lists of subsidized medicines (these lists are called formularies). Unless they provide subsidies, it is unlikely that Truvada will reach its full potential to significantly stem the spread of HIV.

Resources

Truvada – CATIE fact sheet

Pre-exposure prophylaxis (PrEP) – CATIE fact sheet

CATIE statement on the use of pre-exposure prophylaxis (PrEP) to prevent the sexual transmission of HIV

Condoms, PrEP, and the use of antiretroviral treatment to prevent HIV – CATIE webinar

PrEP for the prevention of HIV infection in the United States: A clinical practice guideline – US Centers for Disease Control and Prevention (CDC)

Clinical providers' supplement for providing PrEP – CDC

Interim guidance on providing HIV PrEP – Quebec Ministry of Health (French only)

Pre-exposure prophylaxis (PrEP) guidelines – B.C. Centre for Excellence in HIV/AIDS

—Sean R. Hosein

REFERENCES:

  1. Gilead Sciences. Health Canada issues notice of compliance for Gilead's Truvada for reducing the risk of sexually acquired HIV infection. Press Release . 29 th February 2016. Available at: http://www.newswire.ca/news-releases/health-canada-issues-notice-of-compliance-for-gileads-truvada-for-reducing-the-risk-of-sexually-acquired-hiv-infection-570475811.html
  2. Gilead Sciences. Truvada (emtricitabine/tenofovir disoproxil fumarate tablets). Product Monograph . 23 February, 2016.

From Canadian AIDS Treatment Information Exchange (CATIE). For more information visit CATIE's Information Network at http://www.catie.ca

Source: CATIE: CANADIAN AIDS TREATMENT INFORMATION EXCHANGE


For more HIV and AIDS News visit...

Positively Positive - Living with HIV/AIDS:
HIV/AIDS News


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik
uks.jpg

Copyright © 2003-2017 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS

spacer.gif